Analysis Tools
digestive/alimentary system
|
• pIpC injected mice exhibit a modest (24%) increase in goblet cells 10 days after pIpC treatment and this difference resolves by 8 weeks indicting a transient goblet cell hyperplasia
|
endocrine/exocrine glands
|
• mice injected with polyinosinic-polycytidylic acid (pIpC) exhibit thymus cellularity reduced by about 4- to 5-fold compared to controls
• however, bone marrow or splenic cellularity are not affected
• mice injected with pIpC show reduced numbers of all thymic T cell subsets
|
hematopoietic system
|
• mice injected with polyinosinic-polycytidylic acid (pIpC) exhibit thymus cellularity reduced by about 4- to 5-fold compared to controls
• however, bone marrow or splenic cellularity are not affected
• mice injected with pIpC show reduced numbers of all thymic T cell subsets
|
|
• competitive transplant assays show a modest cell-autonomous loss of B cell subsets generated by pIpC treated mutant bone marrow
• however, pIpC injected mice do not develop myeloproliferative disease, show normal myeloid cell development, and show unaffected hematopoietic stem/progenitor cell numbers
|
|
• pIpC injected mice show an approximate 2-fold loss of NK cell numbers
|
|
• competitive transplant assays show a 3-5 fold reduction in peripheral T cells generated by pIpC treated mutant bone marrow
|
immune system
|
• mice injected with polyinosinic-polycytidylic acid (pIpC) exhibit thymus cellularity reduced by about 4- to 5-fold compared to controls
• however, bone marrow or splenic cellularity are not affected
• mice injected with pIpC show reduced numbers of all thymic T cell subsets
|
|
• competitive transplant assays show a modest cell-autonomous loss of B cell subsets generated by pIpC treated mutant bone marrow
• however, pIpC injected mice do not develop myeloproliferative disease, show normal myeloid cell development, and show unaffected hematopoietic stem/progenitor cell numbers
|
|
• pIpC injected mice show an approximate 2-fold loss of NK cell numbers
|
|
• competitive transplant assays show a 3-5 fold reduction in peripheral T cells generated by pIpC treated mutant bone marrow
|
neoplasm
|
• mutant bone marrow stem cells transduced with Notch1 mutants and transplanted into recipient mice which when injected with pIpC show impaired initiation and maintenance of Notch-induced T cell acute lymphoblastic leukemia
|
